SR9009 (Stenabolic) CAS 1379686-30-2 1000MG / 1 GRAM

SR9009 (Stenabolic)  CAS 1379686-30-2 1000MG / 1 GRAM

What is SR9009?

Stenabolic (SR9009) is a PPAR alpha modifier drug that is still in development as of 2015. Its creator is professor Thomas Burris of the Scripps research institute. Interestingly, it is sold as a SARM and research chemical, and it can be compared to Cardarine (GW-501516), as it is also an agonist of Rev-ErbA. According to an article by "National Medicine," it enhances exercise capacity in mice by increasing mitochondria in skeletal muscle. This is why it has been marketed and hyped around the internet as "exercise in a bottle."

What is the result after using it?
Stenabolic (SR9009) will help a person become leaner, and it will help them do more distance with cardio without getting winded as fast. Overall, it will increase your VO2 max, allowing you to improve your endurance.
Additionally, SR9009 can benefit non athletes as well, since it can reverse obesity, metabolic syndrome, and type 2 diabetes.

More informationabout SR9009
A new drug known as SR9009, which is presently under development at TSRI (The Scripps Research Institute) has been shown to considerably boost exercise endurance in animal models. Scientists think these discoveries may lead to improved cures for individuals suffering from illnesses that severely limit exercise endurance such as obesity, COPD (chronic obstructive pulmonary disease), congestive heart failure and also in the deterioration of muscle capacity linked with aging.